Granted Patent
B2
US 12,398,425 · App. 18/128,949 · Granted Aug 26, 2025
Antidote-mediated reversal of extracellular aptamer staining
Assignee:
DUKE UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.
Claims (9)
1. An aptamer conjugate comprising a multiplicity of aptamers each comprising a binding label, wherein the binding label of each of the multiplicity of aptamers is complexed to a linker, the linker comprising a reporter label and/or a magnetic label.
2. The aptamer conjugate of claim 1 , wherein the binding label comprises biotin and the linker comprises streptavidin.
3. The aptamer conjugate of claim 1 , wherein the reporter label comprises a fluorophore moiety.
4. The aptamer conjugate of claim 1 , wherein the multiplicity of aptamers comprises two aptamers each comprising a binding label complexed to the same linker.
5. The aptamer conjugate of claim 1 , wherein the aptamer is a multivalent aptamer comprising a multiplicity of binding motifs.
6. The aptamer conjugate of claim 5 , wherein each of the multiplicity of binding motifs are the same.
7. The aptamer conjugate of claim 5 , wherein each of the multiplicity of binding motifs are different.
8. The aptamer conjugate of claim 1 , wherein the reporter label comprises one or more of a fluorophore moiety, an optical moiety, a radiolabel moiety, an X-ray moiety; an ultrasound imaging moiety, a photoacoustic imaging moiety, a nanoparticle-based moiety.
9. The aptamer conjugate of claim 1 , wherein the aptamer is unbound from its molecular target.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 31, 2023
From: SULLENGER, BRUCE; GRAY, BETHANY; NICHOLS, MICHAEL
To: DUKE UNIVERSITY
Reel/Frame 063195/0127 →
Continuity (3)
Division
16496871
Provisional Application
62475315
· Mar 23, 2017
References Cited (98)
US 7741307B2
· Sullenger et al.
· 2010
[cited by applicant]
US 7776836B2
· Sullenger et al.
· 2010
[cited by applicant]
US 8367627B2
· Sullenger et al.
· 2013
[cited by applicant]
US 8790924B2
· Sullenger et al.
· 2014
[cited by applicant]
US 9061043B2
· Sullenger et al.
· 2015
[cited by applicant]
US 9687529B2
· Sullenger et al.
· 2017
[cited by applicant]
US 9873727B2
· Sullenger et al.
· 2018
[cited by applicant]
US 9958448B2
· Halbert et al.
· 2018
[cited by applicant]
US 20090130650A1
· Tan et al.
· 2009
[cited by applicant]
US 20100076060A1
· Sullenger et al.
· 2010
[cited by applicant]
US 20100267802A1
· Sullenger
· 2010
[cited by applicant]
US 20140296095A1
· Lin et al.
· 2014
[cited by applicant]
US 20140348755A1
· Weng
· 2014
[cited by applicant]
JP 2007319153
· 2007
[cited by applicant]
WO 2004081021
· 2004
[cited by applicant]
WO 2009045545
· 2009
[cited by applicant]
WO 2010120518
· 2010
[cited by applicant]
WO 2014121256
· 2014
[cited by applicant]
WO 2014169049
· 2014
[cited by applicant]
WO 2015048173
· 2015
[cited by applicant]
WO 2015066027
· 2015
[cited by applicant]
WO 2015188839
· 2015
[cited by applicant]
WO 2016025804
· 2016
[cited by applicant]
WO 2018119422
· 2018
[cited by applicant]
Allerson, C. R. et al. “Fully 2′-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA.” J. Med. Chem 48 (2005): 901-904.
[cited by applicant]
Becker et al., “Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application,” (2005) Thromb. Haemost. 93:1014-1020.
[cited by applicant]
Bompiani et al., “A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity,” (2012) J Thromb Haemost 10:870-80.
[cited by applicant]
Bonner, W. A., et al. “Fluorescence activated cell sorting.” Review of Scientific Instruments 43.3 (1972): 404-409.
[cited by applicant]
Burmeister, P. E., et al. “Direct in vitro selection of a 2′-O-methyl aptamer to VEGF.” Chemistry & biology 12.1 (2005): 25-33.
[cited by applicant]
Champlin, R. E. et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95: 3996-4003.
[cited by applicant]
Chan et al. “Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease” (2008) Circulation 117:2865-2874.
[cited by applicant]
Chan et al., “A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor,” (2008) Journal of Thrombosis & Haemostasis 6:789-796.
[cited by applicant]
Copelan, E. A. “Hematopoietic stem-cell transplantation.” New England Journal of Medicine 354.17 (2006): 1813-1826.
[cited by applicant]
Dyke et al., “First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa act…
[cited by applicant]
Ellington et al., “In vitro selection of RNA molecules that bind specific ligands.” (1990) Nature 346:818-22.
[cited by applicant]
Extended European Search Report dated Oct. 22, 2020 for European Application No. 18770523.1 (11 pages).
[cited by applicant]
Farokhzad, O.C. et al. “Nanoparticle aptamer bioconjugates: A new approach for targeting prostate cancer cells,” (2004) Cancer Research 64:7668-7672.
[cited by applicant]
Franciscis et al., “Nucleic Acid Aptamers for In Vivo Molecular Imaging,” (2012) Molecular Imaging Chapter 5.
[cited by applicant]
Guo, K-T. et al A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High-Specific DNA Aptamers, Stem Cells 2006 24:220-2231.
[cited by applicant]
Handgretinger, R. “Negative depletion of CD3+ and TcRaß+ T cells.” Current opinion in hematology 19.6 (2012): 434-439.
[cited by applicant]
Handgretinger, R., et al. “Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting.” Bone marrow transplantation 21.10 (1998): 987-993.
[cited by applicant]
Herdewijn P, “Heterocyclic modifications of oligonucleotides and antisense technology,” (2000) Antisense Nucleic Acid Drug Development 10:297.
[cited by applicant]
Herzenberg, L. A. et al. “The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford.” Clinical chemistry 48.10 (2002): 1819-1827.
[cited by applicant]
Heslop, H. E. et al. “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.” Nature medicine 2.5 (1996): 551-555.
[cited by applicant]
Hoffman et al., “A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation,” (1992) Am. J. Clin. Pathol. 98:531-533.
[cited by applicant]
Holliger, P., et al. (2005). Engineered antibody fragments and the rise of single domains. Nature biotechnology, 23(9), 1126-1136.
[cited by applicant]
Hwang, W. Y. K., et al. (2005). Immunogenicity of engineered antibodies. Methods, 36(1), 3-10.
[cited by applicant]
International Searching Authority, International Search Report and Written Opinion for application PCT/US2018/024075. Mailed on Jun. 21, 2018.
[cited by applicant]
James et al., “A molecular imaging primer: modalities, imaging agents, and applications,” (2012) Physiol Rev 92(2):897-965.
[cited by applicant]
Joachimi, A. et al., “A new anticoagulant-antidote pair: Control of thrombin activity by aptamers and porphyrins,” (2007) Journal of the American Chemical Society 129(11):3036-3037.
[cited by applicant]
June, C. H. “Adoptive T cell therapy for cancer in the clinic.” The Journal of clinical investigation 117.6 (2007): 1466-1476.
[cited by applicant]
Kandimalla, E.R. et al. “Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides.” Nucleic Acids Res. Sep. 11, 1995; 23(17): 3578-3584.
[cited by applicant]
Kaufman, E. N., et al. (1992). Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer r…
[cited by applicant]
Labib, M. et al., “Aptamer and Antisense-Mediated Two-Dimensional Isolation of Specific Cancer Cell Subpopulations,” J.Am. Chem. Soc. 2016; 138:2476-2479.
[cited by applicant]
Li, N., et al. “Inhibition of cell proliferation by an anti-EGFR aptamer.” PloS one 6.6 (2011): e20299.
[cited by applicant]
Locatelli, F., et al. “Negative depletion of a/ß+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.” Immunology let…
[cited by applicant]
Mackensen, A., et al. “Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.” Journal of Clinical Oncology 24.31 (2006): 5060-5069.
[cited by applicant]
Maier, K. E., et al. (2016). A new transferrin receptor aptamer inhibits new world hemorrhagic fever mammarenavirus entry. Molecular Therapy-Nucleic Acids, 5, e321.
[cited by applicant]
Masui, H., et al. (1993). Consumption of EGF by A431 cells: evidence for receptor recycling. The Journal of cell biology, 120(1), 85-93.
[cited by applicant]
Mattanovich, D. et al. “Applications of cell sorting in biotechnology.” Microbial cell factories 5.1 (2006): 1-11.
[cited by applicant]
Nimjee et al., “A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery,” (2006) Mol. Ther. 14:408-45.
[cited by applicant]
Nimjee et al., “Aptamers as Therapeutics,” (2017) Annual review of pharmacology and toxicology 57:61-79.
[cited by applicant]
Nimjee, S.M. et al. “Aptamers: an emerging class of therapeutics,” (2005) Annual review of medicine 56:555-83.
[cited by applicant]
Nimjee et al., “Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor,” (2012) Molecular therapy : the journal of the American Society of Gene Therapy 20:391-7.
[cited by applicant]
Office Action for U.S. Appl. No. 16/496,871 mailed Nov. 5, 2021.
[cited by applicant]
Oney, et al., “Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers,” (2007) Oligonucleotides 17(3):265-274—Abstract.
[cited by applicant]
Oney, S. et al., “Development of universal antidotes to control aptamer activity,” (2009) Nature Medicine, 15(10):1224-1229.
[cited by applicant]
Padilla, R. et al. “A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs.” Nucleic acids research 30.24 (2002): e138-e138.
[cited by applicant]
Padilla, R. et al. “Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutant T7 RNA polymerase (RNAP).” Nucleic acids research 27.6 (1999): 1561-1563.
[cited by applicant]
Ray, P. et al. “Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.” Nucleic acid therapeutics 22.5 (2012): 295-305.
[cited by applicant]
Riddell, S. R. et al. “Principles for adoptive T cell therapy of human viral diseases.” Annual review of immunology 13.1 (1995): 545-586.
[cited by applicant]
Rusconi, C.P. et al., “Antidote-mediated control of an anticoagulant aptamer in vivo,” (2004) Nature Biotechnology 22(11):1423-1428.
[cited by applicant]
Rusconi, C.P. et al., “RNA aptamers as reversible antagonists of coagulation factor IXa,” (2002) Nature 419(5):90-94.
[cited by applicant]
Sako, Y. et al. “Single-molecule imaging of EGFR signalling on the surface of living cells.” Nature cell biology 2.3 (2000): 168-172.
[cited by applicant]
Schlessinger, J. “Autoinhibition control.” Science 300.5620 (2003): 750-752.
[cited by applicant]
Schlessinger, J. “Common and distinct elements in cellular signaling via EGF and FGF receptors.” Science 306.5701 (2004): 1506-1507.
[cited by applicant]
Schmidt-Ullrich, R. K., et al. “Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.” Oncogene 15.10 (1997): 1191-1197.
[cited by applicant]
Soutschek, J., et al. “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.” Nature 432.7014 (2004): 173-178.
[cited by applicant]
Steen-Burrell et al., “Development of an Antidote-Controlled RNA Probe for Molecular Thrombi Imaging,” Abstract submitted to Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Meeting. May 2015.
[cited by applicant]
Sykes, M. et al. “Treatment of severe autoimmune disease by stem-cell transplantation.” Nature 435.7042 (2005): 620-627.
[cited by applicant]
Tuerk et al., “Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase,” (1990) Science 249:505-10.
[cited by applicant]
White, R. et al., “Generation of Species Cross-reactive Aptamers Using Toggle SELEX,” (2001) Molecular Therapy 4(6):567-573.
[cited by applicant]
Wong et al., “A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions,” (1993) Proc Natl Acad Sci USA 90(12): 5428-5432.
[cited by applicant]
Drolet et al., “An enzyme-linked oligonucleotide assay,” (1996) Nat. Biotechnol. 14:1021-1025.
[cited by applicant]
Fahmy et al, “Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting,” Biomaterials, 2005, 26, 5727-5736.
[cited by applicant]